HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2.

Abstract
Other groups have reported a superior antitumor efficacy of polyethylene glycol-modified interleukin-2 (PEG-IL-2) compared with regular recombinant interleukin-2 (rIL-2). However, detailed comparison of the antitumor efficacies of locally applied PEG-IL-2 and rIL-2 in the well-established DBA/2-SL2 model shows a higher antitumor efficacy of PEG-IL-2 only at doses < 800 micrograms IL-2 protein/kg body weight. At doses > 800 micrograms IL-2 protein/kg body weight, rIL-2 has better therapeutic efficacy. The superiority of rIL-2 at doses > 800 micrograms IL-2 protein/kg body weight is a result of the toxicity of PEG-IL-2 at these doses. With either IL-2 preparation, cure rates of approximately 90% can be obtained at nontoxic doses. We conclude that PEG-IL-2 does not have superior antitumor efficacy to rIL-2. The main advantage of PEG-IL-2 is that for optimal therapeutic efficacy a daily injection schedule is not required as seems to be the case for rIL-2.
AuthorsM R Bernsen, H F Dullens, W Den Otter, P M Heintz
JournalJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research (J Interferon Cytokine Res) Vol. 15 Issue 7 Pg. 641-5 (Jul 1995) ISSN: 1079-9907 [Print] United States
PMID7553236 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Interleukin-2
  • Recombinant Proteins
  • interleukin-2, polyethylene glycol-modified
  • Polyethylene Glycols
Topics
  • Animals
  • Antineoplastic Agents (therapeutic use, toxicity)
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Evaluation Studies as Topic
  • Female
  • Injections
  • Interleukin-2 (analogs & derivatives, therapeutic use, toxicity)
  • Lymphoma, Non-Hodgkin (drug therapy)
  • Mice
  • Mice, Inbred DBA
  • Neoplasm Transplantation
  • Polyethylene Glycols
  • Random Allocation
  • Recombinant Proteins (therapeutic use, toxicity)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: